Key takeaways:
Vyndaqel (tafamidis meglumine) and Vyndamax (tafamidis) are both used to treat the wild-type and hereditary forms of transthyretin amyloid cardiomyopathy (ATTR-CM).
Vyndaqel and Vyndamax contain different forms of tafamidis. Both versions work the same way in the body. The Vyndamax dosage is one pill daily. But Vyndaqel contains a smaller amount of tafamidis, so you need to take four pills instead.
Both Vyndaqel and Vyndamax are only available as brand-name medications. By using a manufacturer copay card, you could pay as little as $0 per month for your prescription.
In May 2019, Vyndaqel and Vyndamax became the first medications approved to treat wild-type and hereditary forms of transthyretin amyloid cardiomyopathy (ATTR-CM). They were also the first medications in their class — transthyretin (TTR) stabilizers.
If you’re prescribed Vyndaqel, you need to take four pills per dose. With Vyndamax, you only take one pill. But why is that? The short answer: It has to do with their ingredients. Below, we help you understand the difference between these two medications.
Vyndaqel and Vyndamax both contain the same active ingredient: tafamidis. But Vyndaqel contains a salt form called tafamidis meglumine. Vyndamax contains the free acid form of tafamidis.
Vyndaqel and Vyndamax are considered bioequivalent. This means that the active component (tafamidis) is absorbed in a similar amount and at a similar rate. In other words, Vyndaqel and Vyndamax should work the same way in the body. But the two products aren’t interchangeable on a per-milligram basis. This is why they require different dosages.
Vyndaqel comes as 20 mg capsules. Each capsule contains 20 mg of tafamidis meglumine, which is equivalent to 12.2 mg tafamidis. Vyndamax comes as 61 mg capsules that each contain 61 mg of tafamidis. Vyndaqel and Vyndamax capsules are the same size.
Since each Vyndaqel capsule contains a smaller amount of tafamidis, you need to take four capsules as a once-daily dose. Vyndamax was developed as a more convenient option. Since each capsule contains more tafamidis, you only need to take one capsule per day.
Since the two medications are considered to be bioequivalent, your healthcare provider can switch you from Vyndaqel to Vyndamax. If you take a lot of pills every day, switching can help you cut down on how many you take. But is it safe to make the switch?
After the initial Vyndaqel clinical trial, people were followed to study the long-term benefits of treatment. During this study, everyone taking Vyndaqel was transitioned to Vyndamax. Side effects were similar, and there were no new safety concerns with Vyndamax.
Whether you’re taking Vyndaqel or Vyndamax, there are ways to save on your prescription. Both medications are made by the same manufacturer, which offers a copay savings card to make your prescription more affordable. If you’re eligible, you could pay as little as $0 per month for Vyndaqel or Vyndamax.
Good to know: Vyndaqel and Vyndamax are considered specialty medications, so you’ll usually receive them in the mail from a specialty pharmacy. Pharmacy staff will work with your insurance to figure out your coverage and prescription cost. They’ll also help you understand if you’re eligible for any financial assistance.
Vyndaqel (tafamidis meglumine) and Vyndamax (tafamidis) are two medications that contain different forms of the same active ingredient. They’re considered bioequivalent, so you should expect similar results from both products.
If you’re prescribed Vyndaqel, you’ll need to take four capsules once daily. With Vyndamax, you only need to take one capsule per day. Taking fewer pills can be a more convenient option for some people. If you’re interested, you can talk to your healthcare provider about switching to Vyndamax from Vyndaqel.
American Heart Association. (2021). Transthyretin amyloid cardiomyopathy (ATTR-CM).
Elliott, P., et al. (2022). Long-term survival with tafamidis in patients with transthyretin amyloid cardiomyopathy. Circulation: Heart Failure.
Marsh, D. E. S. (2023). Bioequivalence and interchangeability of generic drugs. Merck Manual.
Pfizer Inc. (2019). U.S. FDA approves Vyndaqel and Vyndamax for use in patients with transthyretin amyloid cardiomyopathy, a rare and fatal disease. Business Wire.
Pfizer Inc. (2021). Pfizer’s Vyndaqel/Vyndamax reduced the risk of all-cause mortality by 41% among patients with transthyretin amyloid cardiomyopathy, five-year follow-up data demonstrate.
Pfizer Inc. (2023). Vyndaqel / Vyndamax labeling.
Pfizer Laboratories Division, Pfizer Inc. (2023). Vyndaqel - tafamidis meglumine capsule, liquid filled [package insert], and Vyndamax - tafamidis capsule, liquid filled [package insert].
Research prescriptions and over-the-counter medications from A to Z, compare drug prices, and start saving.